Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
-30.0%
0%
-30.0%
1 Year
-17.65%
0%
-17.65%
2 Years
-44.44%
0%
-44.44%
3 Years
-49.64%
0%
-49.64%
4 Years
-71.89%
0%
-71.89%
5 Years
-81.58%
0%
-81.58%
Incanthera Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.56
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.53
EV to EBIT
-1.42
EV to EBITDA
-1.42
EV to Capital Employed
2.65
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-186.11%
ROE (Latest)
-134.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Mar'23
Mar'23
Mar'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.90
-1.00
10.00%
Interest
0.00
0.00
Exceptional Items
-0.50
0.00
Consolidate Net Profit
-1.40
-1.00
-40.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Mar 2023 is 0.00% vs 0.00% in Mar 2022
Consolidated Net Profit
YoY Growth in year ended Mar 2023 is -40.00% vs -11.11% in Mar 2022
About Incanthera Plc 
Incanthera Plc
Pharmaceuticals & Biotechnology
Incanthera plc is a United Kingdom-based specialist oncology company focused on transforming cancer treatment. The Company’s lead product and focus is Sol, a topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company’s products include EP0015, Equin and Duo-C. EP0015 targets the treatment of adult solid cancers remains palliative rather than curative and represents a unmet need. Equin is a quinone-based prodrug activated by the enzyme DT-diaphorase (DTD) which itself is over-expressed in many solid tumours, including breast, colon, liver, bladder, stomach, the central nervous system (CNS), lung tumours and in melanomas. Duo-C focuses upon targeting colorectal cancer using duocarmycins, which are recognized for their extreme cytotoxicity, converted to a prodrug and designed to overcome their intrinsic toxicity and make them manageable and useful in the clinical set up.






